Fundraising Fox
Orchard Therapeutics
London, GB · Founded 2018 · Incorporated in United Kingdom · 239 employees on LinkedIn · 11 known investors
Find your way into Orchard Therapeutics
Sign up to see every warm intro you have to Orchard Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Orchard Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy. The Nasdaq-listed biotech (ticker ORTX) has commercialized therapies including Strimvelis and Libmeldy in Europe.
Founders & leadership
Orchard Therapeutics was founded in 2018 by Donald Kohn and Adrian Thrasher.
Board
Investors · 11
How we know: AlbionVC's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: F-Prime Capital's portfolio page · a partner's Signal profile · fiercebiotech.com · Not right? Tell us
How we know: Foresite Capital's portfolio page · Not right? Tell us
How we know: fiercebiotech.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: funding news · fiercebiotech.com · Not right? Tell us
How we know: funding news · fiercebiotech.com · Not right? Tell us
How we know: funding news · fiercebiotech.com · Not right? Tell us
Also in the syndicate · 1
Funding
SEC filings, press & company announcements$294M disclosed across 3 of 4 rounds · 2017–2023
- $110MSeries BDec 2017 · 2 sources
Baillie Gifford (lead), ORI Capital (lead), Cowen Healthcare Investments, F-Prime Capital, Juda Capital, Temasek, UCL Technology Fund
Source ↗
▶$34MraisedMar 2023 · 7 investors · BiotechnologyRule 506(b)
- James A. GeraghtyDirector
- Joanne T. BeckDirector
- Bobby GasparExecutive Officer, Director
- Marc DunoyerDirector
- Steven M. AltschulerDirector
- Frank E. ThomasExecutive Officer
- Alicia SecorDirector
- Charles Rowland, Jr.Director
- John CurnutteDirector
- Amount sold
- $34M
- Sales commissions
- $3.2M
- Placement agents
- GUGGENHEIM SECURITIES, LLC
- First sale
- Mar 2023
- Incorporated
- Other, United Kingdom, 2018
- Federal exemptions
- 06b
▶$150MraisedFeb 2021 · 24 investors · BiotechnologyRule 506(b)
- Steven AltschulerDirector
- Frank E. ThomasExecutive Officer
- John CurnutteDirector
- Charles Rowland Jr.Director
- Alicia SecorDirector
- Jon EllisDirector
- James A. GeraghtyDirector
- Joanne T. BeckDirector
- Bobby GasparExecutive Officer, Director
- Marc DunoyerDirector
- Offering amount
- $150M
- Amount sold
- $150M
- Sales commissions
- $6M
- Placement agents
- Oppenheimer & Co. Inc., Cantor Fitzgerald & Co., Cowen and Company, LLC
- First sale
- Feb 2021
- Incorporated
- Other, United Kingdom, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Orchard Therapeutics.
Companies House · registry record
View on Companies House ↗- Registered name
- ORCHARD THERAPEUTICS LIMITED
- Company number
- 11494381
- Status
- Dissolved
- Company type
- Private limited company
- Incorporated
- 1 Aug 2018
- Dissolved
- 20 Jan 2026
- Registered office
- 245 Hammersmith Road, 3rd Floor, London, W6 8PW
- Nature of business (SIC)
- 64209 — Activities of other holding companies n.e.c.72110 — Research and experimental development on biotechnology
- Previous names
- ORCHARD THERAPEUTICS PLC (2018–2024)ORCHARD THERAPEUTICS LIMITED (2018–2018)ORCHARD RX LIMITED (2018–2018)
- Accounts
- last made up to 31 Dec 2023
- Confirmation statement
- last made up to 7 Feb 2025
Current officers
- Christopher Tappan York — secretary, appointed 28 Feb 2022
- Jonathan Henry Welbore Ellis — director, appointed 22 Feb 2024
- Yasuo Fujii — director, appointed 24 Jan 2024
- Hubert Baburaj Gaspar — director, appointed 3 Oct 2018
- Abdul Hafeez Mullick — director, appointed 24 Jan 2024
- Takeyoshi Yamashita — director, appointed 24 Jan 2024
Source: Companies House public register · retrieved 23 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Orchard Therapeutics do?
- Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy. The Nasdaq-listed biotech (ticker ORTX) has commercialized therapies including Strimvelis and Libmeldy in Europe.
- Who founded Orchard Therapeutics?
- Orchard Therapeutics was founded by Donald Kohn, Adrian Thrasher in 2018.
- Who are Orchard Therapeutics's investors?
- Orchard Therapeutics's investors include AlbionVC, F-Prime Capital, Foresite Capital, UCL Technology Fund, 4BIO Capital, Agent Capital, Baillie Gifford, Cowen Healthcare Investments and 2 more.
- How much funding has Orchard Therapeutics raised?
- Orchard Therapeutics has disclosed $294M raised across 3 of its 4 known rounds.
- Where is Orchard Therapeutics headquartered?
- Orchard Therapeutics is headquartered in London, GB.